CV/NASH play Madrigal finds public path via Synta merger

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) and Madrigal Pharmaceuticals Inc. (Fort Washington, Pa.) will reverse-merge to create a company focused on non-alcoholic steatohepatitis (NASH), cardiovascular and metabolic diseases. The combined, publicly traded company will retain Madrigal's

Read the full 343 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE